GT Biopharma, Inc. (GTBP)
GTBP moved a median of -0.91% 30 minutes after news, and -0.68% by the close. How GTBP actually reacts to news — the realized, point-in-time move the market made, measured across 159 labeled events over the last three years with zero look-ahead.
GTBP’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.13% | 30% | 147 |
| 30-min | -0.91% | 32% | 150 |
| 60-min | -0.51% | 37% | 153 |
| to close | -0.68% | 42% | 159 |
| Middle 50% of GTBP reactions | -3.02% to +0.67% |
|---|---|
| Median reaction (30-min) | -0.91% |
| Measured reactions | 159 |
Half of all GT Biopharma, Inc. news events land between -3.02% and +0.67% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when GTBP moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to GTBP's baseline. Nothing else.
Recent GTBP events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form DEF 14A GT Biopharma, Inc. For: Oct 13 | SEC filing · Form DEF | SEC EDGAR | +0.00% | -3.57% | |
| Form S-1 GT Biopharma, Inc. | SEC filing · Form S-1 | SEC EDGAR | -3.98% | +0.15% | |
| Form PRE 14A GT Biopharma, Inc. For: Oct 02 | SEC filing · Form PRE | SEC EDGAR | +0.00% | +0.00% | |
| Form D GT Biopharma, Inc. | SEC filing · Form D | SEC EDGAR | — | +1.40% | |
| Form 8-K GT Biopharma, Inc. For: Sep 22 | SEC filing · Form 8-K | SEC EDGAR | -0.36% | -2.86% | |
| Form 8-K GT Biopharma, Inc. For: Sep 18 | SEC filing · Form 8-K | SEC EDGAR | -1.54% | +0.84% | |
| Form 8-K GT Biopharma, Inc. For: Sep 14 | SEC filing · Form 8-K | SEC EDGAR | -9.71% | -14.12% | |
| GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma | Press release | GlobeNewswire | -9.71% | -14.12% | |
| GT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026 | Press release | GlobeNewswire | +4.55% | +30.65% | |
| Form 8-K GT Biopharma, Inc. For: Sep 02 | SEC filing · Form 8-K | SEC EDGAR | -0.74% | -10.59% | |
| Form 10-Q GT Biopharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.42% | +0.34% | |
| Form 8-K GT Biopharma, Inc. For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | +1.00% | -1.72% | |
| GT Biopharma Reports Second Quarter 2026 Financial Results | Press release | GlobeNewswire | +1.42% | +0.34% | |
| Form DEF 14A GT Biopharma, Inc. For: Jul 02 | SEC filing · Form DEF | SEC EDGAR | -5.91% | +0.16% | |
| Form PRE 14A GT Biopharma, Inc. For: Jun 18 | SEC filing · Form PRE | SEC EDGAR | +1.85% | -8.35% | |
| After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell | Press release | GlobeNewswire | -2.85% | -0.56% | |
| Form 8-K GT Biopharma, Inc. For: Jun 08 | SEC filing · Form 8-K | SEC EDGAR | -4.87% | -3.70% | |
| Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet | Press release | GlobeNewswire | -1.98% | -6.34% | |
| A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company | Press release | PR Newswire | -1.15% | +5.56% | |
| GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives | Press release | GlobeNewswire | -2.87% | -9.80% | |
| Form 8-K GT Biopharma, Inc. For: May 20 | SEC filing · Form 8-K | SEC EDGAR | -0.86% | +0.00% | |
| B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic | Press release | Canada Newswire | -0.01% | -0.20% | |
| Form 10-Q GT Biopharma, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -10.81% | -12.56% | |
| GT Biopharma Reports First Quarter 2026 Financial Results | Press release | GlobeNewswire | -10.81% | -12.56% | |
| "Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies | Press release | GlobeNewswire | -0.56% | +2.69% | |
| A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology | Press release | GlobeNewswire | +7.67% | +17.35% | |
| Form EFFECT GT Biopharma, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +7.67% | +17.35% | |
| GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors | Press release | GlobeNewswire | +7.67% | +17.35% | |
| Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase | Press release | PR Newswire | +7.67% | +17.35% | |
| Form S-1 GT Biopharma, Inc. | SEC filing · Form S-1 | SEC EDGAR | +2.26% | +4.98% | |
| Form 8-K GT Biopharma, Inc. For: Apr 03 | SEC filing · Form 8-K | SEC EDGAR | -0.35% | +0.02% | |
| GT Biopharma to Participate in the 38th Annual Roth Conference | Press release | GlobeNewswire | +0.02% | +2.56% | |
| Form 10-Q/A GT Biopharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -4.26% | -9.35% | |
| Form 10-Q/A GT Biopharma, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -4.26% | -9.35% | |
| Form 10-K GT Biopharma, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.67% | +0.95% | |
| Form 8-K GT Biopharma, Inc. For: Mar 01 | SEC filing · Form 8-K | SEC EDGAR | +0.67% | +0.95% | |
| GT Biopharma Reports Full Year 2025 Financial Results | Press release | GlobeNewswire | +0.67% | +0.95% | |
| GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference | Press release | GlobeNewswire | -0.18% | -3.67% | |
| GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3 | Press release | GlobeNewswire | +4.04% | +0.95% | |
| Form EFFECT GT Biopharma, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -2.14% | -21.49% | |
| Form S-1 GT Biopharma, Inc. | SEC filing · Form S-1 | SEC EDGAR | +1.32% | +2.03% | |
| GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers | Press release | GlobeNewswire | -3.64% | -2.67% | |
| Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge | Press release | GlobeNewswire | -3.63% | +3.07% | |
| Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines | Press release | PR Newswire | -1.97% | -0.41% | |
| Form EFFECT GT Biopharma, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -3.65% | -22.05% | |
| Form 8-K GT Biopharma, Inc. For: Nov 20 | SEC filing · Form 8-K | SEC EDGAR | -2.13% | -0.87% | |
| GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials | Press release | ACCESS Newswire | -1.88% | -1.15% | |
| Form 10-Q GT Biopharma, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -8.36% | -8.97% | |
| Form 8-K GT Biopharma, Inc. For: Nov 14 | SEC filing · Form 8-K | SEC EDGAR | -4.00% | +23.60% | |
| GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -4.00% | +23.60% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the GTBP section they belong to.
Where else GTBP is measured.
GTBP earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| DURECT Corporation (DRRX) | 159 | +0.03% | 51% |
| Galmed Pharmaceuticals Ltd. - Ordinary Shares (GLMD) | 159 | -1.80% | 36% |
| ImmuCell Corporation (ICCC) | 159 | 0.00% | 42% |
| CollPlant Biotechnologies Ltd. - Ordinary Shares (CLGN) | 158 | -1.25% | 25% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is GT Biopharma, Inc.'s median reaction calculated?
Every labeled GTBP news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 159 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 32% of GTBP's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does GTBP's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.